ShockWave Medical Inc. (NASDAQ: SWAV) is 56.70% higher on its value in year-to-date trading and has touched a low of $37.16 and a high of $167.06 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SWAV stock was last observed hovering at around $166.57 in the last trading session, with the day’s loss setting it -4.04% off its average median price target of $149.00 for the next 12 months. It is also 9.71% off the consensus price target high of $180.00 offered by 6 analysts, but current levels are -21.29% lower than the price target low of $134.00 for the same period.
Currently trading at $162.53, the stock is 13.55% and 28.91% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.21 million and changing -2.43% at the moment leaves the stock 72.40% off its SMA200. SWAV registered 302.00% gain for a year compared to 6-month gain of 124.96%. The firm has a 50-day simple moving average (SMA 50) of $116.19 and a 200-day simple moving average (SMA200) of $101.03.
The stock witnessed a 32.26% loss in the last 1 month and extending the period to 3 months gives it a 35.35%, and is 2.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.49% over the week and 5.44% over the month.
ShockWave Medical Inc. (SWAV) has around 449 employees, a market worth around $5.63B and $67.80M in sales. Profit margin for the company is -96.90%. Distance from 52-week low is 337.38% and -2.71% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.10%).
ShockWave Medical Inc. (SWAV) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ShockWave Medical Inc. (SWAV) is a “Overweight”. 6 analysts offering their recommendations for the stock have an average rating of 2.50, where 4 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ShockWave Medical Inc. is expected to release its quarterly report on 08/09/2021 and quarterly earnings per share for the current quarter are estimated at -$0.45 with sales reaching $29.9M over the same period.The EPS is expected to grow by 7.10% this year, but quarterly earnings will post 134.50% year-over-year.
ShockWave Medical Inc. (SWAV) Top Institutional Holders
328 institutions hold shares in ShockWave Medical Inc. (SWAV), with 2.21M shares held by insiders accounting for 6.35% while institutional investors hold 116.36% of the company’s shares. The shares outstanding are 34.46M, and float is at 32.01M with Short Float at 7.81%. Institutions hold 108.97% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 5.14 million shares valued at $533.01 million. The investor’s holdings represent 14.75% of the SWAV Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 2.79 million shares valued at $289.68 million to account for 8.02% of the shares outstanding. The other top investors are Price (T.Rowe) Associates Inc which holds 2.48 million shares representing 7.12% and valued at over $257.31 million, while Blackrock Inc. holds 6.88% of the shares totaling 2.4 million with a market value of $248.69 million.
ShockWave Medical Inc. (SWAV) Insider Activity
A total of 174 insider transactions have happened at ShockWave Medical Inc. (SWAV) in the last six months, with sales accounting for 140 and purchases happening 34 times. The most recent transaction is an insider sale by WATKINS FRANK T, the company’s Director. SEC filings show that WATKINS FRANK T sold 2,000 shares of the company’s common stock on Apr 21 at a price of $149.08 per share for a total of $0.3 million. Following the sale, the insider now owns 82952.0 shares.
ShockWave Medical Inc. disclosed in a document filed with the SEC on Apr 21 that PUCKETT DAN (Chief Financial Officer) sold a total of 5,000 shares of the company’s common stock. The trade occurred on Apr 21 and was made at $149.20 per share for $0.75 million. Following the transaction, the insider now directly holds 45788.0 shares of the SWAV stock.
Still, SEC filings show that on Apr 20, WATKINS FRANK T (Director) disposed off 2,000 shares at an average price of $138.35 for $0.28 million. The insider now directly holds 86 shares of ShockWave Medical Inc. (SWAV).